Anagin, Inc. is an Indiana University spin off organized around development of therapies that target mechanisms often characteristic of neuropsychiatric diseases through abnormal neuroplasticity, inflammation, excitotoxicity and neurodegeneration. The effort is to provide disease modifying and curative therapies for patients suffering from these conditions to include post-traumatic stress disorder (PTSD), traumatic brain injury, neuropathic pain, depression, Parkinsons disease and Alzheimers disease. The drugs block the target mechanism of these conditions without triggering others that causes crippling side effects to includes agitation, irritability, sexual dysfunction, drowsiness, memory, motor skill problems, and addiction.
